// App-Quantinova.ai

TPS5596 : Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).

Researchers

Presenter

  • Ignace Vergote

Principal Investigators

  • Robert L. Coleman

  • Leslie M. Randall

  • Keiichi Fujiwara

  • Christian Marth

  • Linn Lena Woelber

  • Els Van Nieuwenhuysen

  • David Cibula

  • Paula Calvert

  • Ingrid Boere

  • Antonio Gonzlez-Martn

  • Elsa Kalbacher

  • Nicoletta Colombo

  • Domenica Lorusso

  • Susana N. Banerjee

  • Fernando C. Maluf

  • Ibrahima Soumaoro

  • Brian M. Slomovitz

Medical Centers

  • Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute, Leuven, Belgium

  • Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, AZ

  • US Oncology Research, The Woodlands, TX

  • Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

  • Saitama Medical University International Medical Center, Hidaka, Japan

  • Arbeitsgemeinschaft Gynäkologische Onkologie Austria (AGO-Austria), Medical University Innsbruck, Innsbruck, Austria

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Central and Eastern European Gynecologic Oncology Group (CEEGOG), Department of Obstetrics and Gynecology and First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Cancer Trials Ireland

  • Dublin, Ireland

  • The Dutch Gynecology Oncology Group, Utrecht, Netherlands

  • GEICO and Clinica Universitaria de Navarra, Madrid, Spain

  • Groupe d’Investigateurs Nationaux pour l’Etute des Cancers Ovariens and CHRU Jean Minjoz, Besançon, France

  • University of Milan-Bicocca and European Institute of Oncology, IRCCS and Mario Negri Gynecologic Oncology Group (MANGO), Milan, Italy

  • Multicentre Italian Trials in Ovarian Cancer and Gynaecological Malignancies Group (MITO) and Scientific Directorate and Department of Women and Child Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

  • The National Cancer Research Institute (NCRI) and The Royal Marsden NHS Foundation Trust, London, United Kingdom

  • Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil

  • Genmab US, Inc,Plainsboro, NJ,USA

  • Broward Health, Fort Lauderdale, FL

Locations

  • Belgium

  • United States

  • Japan

  • Austria

  • Germany

  • Czech Republic

  • Ireland

  • Netherlands

  • Spain

  • France

  • Italy

  • United Kingdom

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cervical cancer

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Carboplatin

  • Gemcitabine

  • Vinorelbine

  • Irinotecan

  • Paclitaxel

  • Pemetrexed

  • Cisplatin

  • Topotecan Hydrochloride

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT04697628

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved